rs17085007 — USP12

USP12 13q12 — A Deubiquitinase Locus Governing UC Relapse Risk

Your immune system continuously balances attack against tolerance. In the colon, that balance is maintained largely by CD4+ T cells that must activate against genuine pathogens while staying restrained toward the gut's own bacterial residents. A variant at chromosome 13q12 — just upstream of the gene encoding USP12, a deubiquitinase that is a critical regulator of CD4+ T cell activation — appears to tip this balance toward persistent inflammation in carriers, manifesting as ulcerative colitis susceptibility and, in established UC patients, a substantially elevated risk of disease relapse.

The Mechanism

USP12 (ubiquitin-specific peptidase 12) is a deubiquitinating enzyme that removes ubiquitin tags from target proteins to prevent their degradation. Its most immunologically consequential substrate is BCL10¹¹ BCL10
B-cell lymphoma/leukemia 10 — a scaffold protein in the CBM signalosome complex that links antigen receptors to NF-κB activation; without BCL10, the TCR cannot efficiently signal through NF-κB. By stabilizing BCL10, USP12 amplifies NF-κB signaling specifically in CD4+ T cells (not CD8+ T cells), driving their proliferation, cytokine production (IFN-γ, TNF-α, IL-2), and inflammatory activity.

The rs17085007 C allele lies within a regulatory region approximately 109 kilobases upstream of the USP12 transcription start site. The variant does not change any amino acid — it is annotated as intergenic with likely regulatory function, consistent with the observation that most IBD GWAS signals fall within gene regulatory elements rather than coding sequences. The precise molecular consequence of the C allele on USP12 expression levels has not been characterized by luciferase assay or CRISPR-based functional validation as of 2026, but the gene-level biology is well-established: altered USP12 dosage or activity produces measurable changes in CD4+ T cell-driven inflammation in animal models.

The Evidence

The 13q12 locus was first identified as a UC susceptibility signal in a Japanese genome-wide association study of 1,384 cases and 3,057 controls, reaching genome-wide significance at P = 6.64 × 10⁻⁸²² P = 6.64 × 10⁻⁸
This P-value threshold (5 × 10⁻⁸) is the conventional GWAS significance threshold, chosen to correct for ~1 million independent tests across the genome; surpassing it provides strong statistical confidence that the association is not a chance finding. The locus was independently replicated in a Korean GWAS, reaching Bonferroni-corrected significance in that East Asian cohort as well, confirming cross-ethnic sharing of the genetic risk signal.

The variant's clinical utility extends beyond susceptibility to predicting disease course. In a prospective Japanese cohort of 109 patients with quiescent ulcerative colitis followed over a mean of 35 months, rs17085007 genotype was a significant independent predictor of relapse. Heterozygous carriers (CT) had more than double the relapse hazard compared to TT homozygotes (adjusted HR 2.16; 95% CI 1.10–4.23; p = 0.03), while CC homozygotes had triple the risk (adjusted HR 3.25; 95% CI 1.18–8.95; p = 0.02)³³ Heterozygous carriers (CT) had more than double the relapse hazard compared to TT homozygotes (adjusted HR 2.16; 95% CI 1.10–4.23; p = 0.03), while CC homozygotes had triple the risk (adjusted HR 3.25; 95% CI 1.18–8.95; p = 0.02)
45% of the 109 subjects relapsed during follow-up; the risk was additive with FCGR2A variants — patients carrying both risk genotypes had a combined HR of 5.40 (95% CI 2.06–14.13; p = 0.0006).

Practical Actions

For UC patients who carry the C risk allele, the key implication is monitoring intensity. Carriers who enter remission face a substantially higher probability of relapse than TT homozygotes — the trial data suggest closer clinical follow-up (more frequent colonoscopy or fecal calprotectin monitoring) is warranted. Aggressive adherence to prescribed maintenance therapy (5-ASA regimens or biologic maintenance) has greater returns for C allele carriers than for low-risk TT homozygotes. The additive interaction with FCGR2A (rs1801274) means carriers of risk alleles at both loci should be identified early in their disease course.

The inflammatory mechanism — excess CD4+ T cell activation via BCL10–NF-κB — points toward immunosuppressive strategies that target T cell activation (calcineurin inhibitors, anti-TNF biologics, vedolizumab) as particularly relevant maintenance options for C allele carriers.

Interactions

rs17085007 shows additive interaction with FCGR2A rs1801274 (also in the autoimmune-inflammation category on this platform): the combined HR for relapse in carriers of both risk variants is 5.40, far exceeding either variant alone. FCGR2A governs myeloid IgG2 clearance efficiency; USP12 13q12 governs T cell activation threshold. The two mechanisms are independent and orthogonal — impaired innate clearance (FCGR2A) combined with a lower T cell activation threshold (USP12 locus) creates a compounding vulnerability in colonic immune homeostasis.